{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:08:35Z","timestamp":1764785315374,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770217","81872322"],"award-info":[{"award-number":["81770217","81872322"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY22H080003","LQ22H080008"],"award-info":[{"award-number":["LY22H080003","LQ22H080008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["2020C03014"],"award-info":[{"award-number":["2020C03014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-024-01039-y","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T14:12:20Z","timestamp":1710166340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of AML1\/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in\u00a0Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.1007","author":[{"given":"Dian","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-3804","authenticated-orcid":false,"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/beha.2000.0114","volume":"14","author":"K Mrozek","year":"2001","unstructured":"Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19\u201347. https:\/\/doi.org\/10.1053\/beha.2000.0114.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1039_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood.V53.4.695.695","volume":"53","author":"JM Trujillo","year":"1979","unstructured":"Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8\/21 translocation acute granulocytic leukemia. Blood. 1979;53:695\u2013706.","journal-title":"Blood"},{"key":"1039_CR3","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1200\/JCO.2001.19.9.2482","volume":"19","author":"K Mrozek","year":"2001","unstructured":"Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19:2482\u201392. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2482.","journal-title":"J Clin Oncol"},{"key":"1039_CR4","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11+<2191::AID-CNCR5>3.0.CO;2-L","volume":"80","author":"CD Bloomfield","year":"1997","unstructured":"Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80:2191\u20138.","journal-title":"Cancer"},{"key":"1039_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X.","journal-title":"Lancet Oncol"},{"key":"1039_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid Leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"1039_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96:208\u201317. https:\/\/doi.org\/10.1002\/ajh.26039.","journal-title":"Am J Hematol"},{"key":"1039_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"key":"1039_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.1976.tb03563.x.","journal-title":"Br J Haematol"},{"key":"1039_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"1039_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/atm.2016.08.57","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2017;5:7. https:\/\/doi.org\/10.21037\/atm.2016.08.57.","journal-title":"Ann Transl Med"},{"key":"1039_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"1039_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"key":"1039_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118.","journal-title":"Genome Res"},{"key":"1039_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106727","volume":"111","author":"D Padmakumar","year":"2021","unstructured":"Padmakumar D, Chandraprabha VR, Gopinath P, Vimala Devi ART, Anitha GRJ, Sreelatha MM, et al. A concise review on the molecular genetics of acute myeloid leukemia. Leuk Res. 2021;111: 106727. https:\/\/doi.org\/10.1016\/j.leukres.2021.106727.","journal-title":"Leuk Res"},{"key":"1039_CR16","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463\u20138. https:\/\/doi.org\/10.1182\/blood-2005-09-3640.","journal-title":"Blood"},{"key":"1039_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","volume":"107","author":"S Schnittger","year":"2006","unstructured":"Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791\u20139. https:\/\/doi.org\/10.1182\/blood-2005-04-1466.","journal-title":"Blood"},{"key":"1039_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4:66\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2019000709.","journal-title":"Blood Adv"},{"key":"1039_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/hematology.2020000087","volume":"2020","author":"EC Chen","year":"2020","unstructured":"Chen EC, Garcia JS. Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? Hematol Am Soc Hematol Educ Program. 2020;2020:41\u201350. https:\/\/doi.org\/10.1182\/hematology.2020000087.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1039_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11899-016-0348-8","volume":"11","author":"HD Klepin","year":"2016","unstructured":"Klepin HD. Definition of unfit for standard acute myeloid leukemia therapy. Curr Hematol Malig Rep. 2016;11:537\u201344. https:\/\/doi.org\/10.1007\/s11899-016-0348-8.","journal-title":"Curr Hematol Malig Rep"},{"key":"1039_CR21","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2021005538.","journal-title":"Blood Adv"},{"key":"1039_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/13543784.2019.1584610","volume":"28","author":"J Cioccio","year":"2019","unstructured":"Cioccio J, Claxton D. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. Expert Opin Investig Drugs. 2019;28:337\u201349. https:\/\/doi.org\/10.1080\/13543784.2019.1584610.","journal-title":"Expert Opin Investig Drugs"},{"key":"1039_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891","volume":"14","author":"GP Sullivan","year":"2022","unstructured":"Sullivan GP, Flanagan L, Rodrigues DA, Ni Chonghaile T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022;14: eabo6891. https:\/\/doi.org\/10.1126\/scitranslmed.abo6891.","journal-title":"Sci Transl Med"},{"key":"1039_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev. 2023;59: 101036. https:\/\/doi.org\/10.1016\/j.blre.2022.101036.","journal-title":"Blood Rev"},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki H, Leppa AM, Polonen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320. https:\/\/doi.org\/10.3324\/haematol.2018.214882.","journal-title":"Haematologica"},{"key":"1039_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710.","journal-title":"Cancer Discov"},{"key":"1039_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339. https:\/\/doi.org\/10.1038\/s43018-020-0103-x.","journal-title":"Nat Cancer"},{"key":"1039_CR28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106:1034\u201346. https:\/\/doi.org\/10.3324\/haematol.2019.244020.","journal-title":"Haematologica"},{"key":"1039_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","volume":"5","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5:1017\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2020003508.","journal-title":"Blood Adv"},{"key":"1039_CR30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/leu.2011.342","volume":"26","author":"KH Metzeler","year":"2012","unstructured":"Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26:1106\u20137. https:\/\/doi.org\/10.1038\/leu.2011.342.","journal-title":"Leukemia"},{"key":"1039_CR31","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.3324\/haematol.2016.148999","volume":"101","author":"CC Coombs","year":"2016","unstructured":"Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016;101:e457\u201360. https:\/\/doi.org\/10.3324\/haematol.2016.148999.","journal-title":"Haematologica"},{"key":"1039_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4274\/tjh.galenos.2022.2021.0641","volume":"39","author":"W Qin","year":"2022","unstructured":"Qin W, Chen X, Shen HJ, Wang Z, Cai X, Jiang N, et al. Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions. Turk J Haematol. 2022;39:84\u201393. https:\/\/doi.org\/10.4274\/tjh.galenos.2022.2021.0641.","journal-title":"Turk J Haematol"},{"key":"1039_CR33","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","volume":"4","author":"N Jahn","year":"2020","unstructured":"Jahn N, Terzer T, Strang E, Dolnik A, Cocciardi S, Panina E, et al. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020;4:6342\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2020002673.","journal-title":"Blood Adv"},{"issue":"22","key":"1039_CR34","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.3390\/cancers15225409","volume":"15","author":"A Alsouqi","year":"2023","unstructured":"Alsouqi A, Geramita E, Im A. Treatment of acute myeloid leukemia in older adults. Cancers (Basel). 2023;15(22):5409.\u00a0https:\/\/doi.org\/10.3390\/cancers15225409.","journal-title":"Cancers (Basel)"},{"key":"1039_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379\u201389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9.","journal-title":"Leukemia"},{"key":"1039_CR36","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","volume":"5","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018;5:e411\u201321. https:\/\/doi.org\/10.1016\/S2352-3026(18)30132-7.","journal-title":"Lancet Haematol"},{"key":"1039_CR37","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40:3848\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02823.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01039-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:13:37Z","timestamp":1712074417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01039-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":37,"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01039-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"31 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by National Natural Science Foundation of China (81770217, 81872322), Natural Science Foundation of Zhejiang Province (LY22H080003, LQ22H080008), and Key Research and Development Project of Zhejiang Province (2020C03014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dian Jin, Haoguang Chen, Jingsong He, Yi Li, Gaofeng Zheng, Yang Yang, Yi Zhao, Jing Le, Wenxiu Shu, Donghua He, and Zhen Cai declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethical Review Committee of The First Affiliated Hospital of Zhejiang University School of Medicine (approval No. IIT20230774A).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The requirement for written informed consent was waived as it was a retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data archiving is not mandated but data will be made available upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and funding acquisition: Donghua He, Zhen Cai; Methodology and Writing - original draft preparation: Dian Jin, Haoguang Chen; Formal analysis: Jingsong He; Investigation: Yi Zhao; Writing - review and editing: Yi Li, Gaofeng Zheng; Resources: Yang Yang, Jing Le, Wenxiu Shu.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}